Abstract
Trastuzumab deruxtecan (ENHERTU (R)), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HE......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
